Deployed close to EUR 1.9 billion of equity* Expanded portfolio to 18 companies, including new investments in Altasciences, BBI, Availity, Esco LifeSciences Group, Medical Knowledge Group and The Ritedose Corporation* Increased the Principal Investments’ portfolio value by more than 30% to excess of EUR 10 billion* Three successful (partial) exits Continued team expansion and established direct […]
Bionical Emas, a global Contract Research Organisation (CRO) providing services to the pharmaceutical and biotech sectors, has appointed Ian Fraser as Executive Vice President (EVP) Clinical Development. Ian will be leading the Clinical Development team across the global business and becomes part of the Senior Leadership Team, reporting to COO, Tom Watson. Read more
BioCity, Scotland, 30th March 2022 £1 million grant will support first-in-human clinical trials of H-Guard Invizius Limited (“Invizius”), a biotechnology company developing treatments to suppress unwanted innate immune responses, today announces that it has been awarded a £1 million grant to bring H-Guard, its proprietary priming solution, designed to reduce the life-threatening inflammatory effects of […]
The funding will accelerate the AI-driven healthcare company’s global market expansion and support new product development Qure.ai (‘Qure’), one of the leading health tech firms using Artificial Intelligence (AI) for medical imaging diagnostics, today announced that it had secured $40 million in a funding round led by Novo Holdings and HealthQuad, supported by existing investor Mass […]
• Started clinical trial with lead candidate RJx-01 for treating sarcopenia • Expands the team and moved to new offices and lab Diepenbeek, Health Campus, Belgium, 29 March 2022 – Rejuvenate Biomed NV (“Rejuvenate”), a biomedical company developing novel combination drugs for age-related diseases, today provides an update on its development pipeline and strategy. Read more…
